The company's stock has zoomed this year, driven by the explosive growth of the weight-loss drug market.
The company’s stock has zoomed this year, driven by the explosive growth of the weight-loss drug market.
By Reuters
Share
Save
Save articles to read later and create your own reading list.
Healthcare giant Eli Lilly is now the first global healthcare company to hit $1 trillion in value riding on the popularity of…
Eli Lilly made 11 biotech acquisitions in H1 2026, dominating the industry's M&A total while targeting vaccines, CAR-T, ADCs &…
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and…
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.
Lilly is the world’s most valuable drugmaker and the first pharmaceutical company to be worth more than $1tr,...
